TY - JOUR
T1 - Survival Trends in Young Patients With Multiple Myeloma
T2 - A Focus on Racial-Ethnic Minorities
AU - Ailawadhi, Sikander
AU - Azzouqa, Abdel Ghani
AU - Hodge, David
AU - Cochuyt, Jordan
AU - Jani, Prachi
AU - Ahmed, Salman
AU - Sher, Taimur
AU - Roy, Vivek
AU - Ailawadhi, Meghna
AU - Alegria, Victoria R.
AU - Manochakian, Rami
AU - Vishnu, Prakash
AU - Grover, Ashna
AU - Abdulazeez, Mays F.
AU - Paulus, Aneel
AU - Chanan-Khan, Asher
N1 - Funding Information:
This study’s analysis utilized funding from the Cancer Focused Research Team (CFRT), Mayo Clinic, Jacksonville, FL.
Funding Information:
S.A. reports institutional research support from Pharmacyclics, Amgen, Cellectar, and Genentech, and has served as a consultant for Takeda, Celgene, Amgen, and Janssen Biotech, Inc. The remaining authors have stated that they have no conflicts of interest.This study's analysis utilized funding from the Cancer Focused Research Team (CFRT), Mayo Clinic, Jacksonville, FL.
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/10
Y1 - 2019/10
N2 - Introduction: Outcomes in multiple myeloma (MM) have improved significantly over time. This is true overall for all patients as well as patient subgroups based on age and race/ethnicity. Despite this, disparities are noted in outcomes when looking at racial subgroups. Materials and Methods: We performed an analysis from the population-based Surveillance, Epidemiology, and End Results (SEER) database to evaluate improvement in relative survival rates (RSRs) for young (≤ 40 years at the time of MM diagnosis) and older (> 40 years at the time of MM diagnosis) over time by race/ethnicity, specifically focusing on Hispanic patients with MM. Expected survival was estimated using the age- and gender-specific death rates from the United States population. RSR was provided as the ratio of the observed to expected survival at individual time points. Five-year and 10-year RSRs were calculated for patients based on treatments modalities available in various time periods. Results: We identified a total of 89,451 patients with MM in SEER, of which 1460 patients formed the young patients with MM (≤ 40 years) cohort. Five- and 10-year RSR improved significantly over time for all patients and older patients (> 40 years) by race (all P < .001). Evaluating the younger patients, RSR improved significantly for non-Hispanic whites and non-Hispanic blacks, but not for Hispanics. This was true for the 5-year (P = .08) and 10-year (P = .13) RSRs. Conclusion: We report a lack of significant benefit in long-term outcomes for younger Hispanic patients with MM over time. This could be owing to multifactorial causes that need to be addressed to mitigate outcome disparities.
AB - Introduction: Outcomes in multiple myeloma (MM) have improved significantly over time. This is true overall for all patients as well as patient subgroups based on age and race/ethnicity. Despite this, disparities are noted in outcomes when looking at racial subgroups. Materials and Methods: We performed an analysis from the population-based Surveillance, Epidemiology, and End Results (SEER) database to evaluate improvement in relative survival rates (RSRs) for young (≤ 40 years at the time of MM diagnosis) and older (> 40 years at the time of MM diagnosis) over time by race/ethnicity, specifically focusing on Hispanic patients with MM. Expected survival was estimated using the age- and gender-specific death rates from the United States population. RSR was provided as the ratio of the observed to expected survival at individual time points. Five-year and 10-year RSRs were calculated for patients based on treatments modalities available in various time periods. Results: We identified a total of 89,451 patients with MM in SEER, of which 1460 patients formed the young patients with MM (≤ 40 years) cohort. Five- and 10-year RSR improved significantly over time for all patients and older patients (> 40 years) by race (all P < .001). Evaluating the younger patients, RSR improved significantly for non-Hispanic whites and non-Hispanic blacks, but not for Hispanics. This was true for the 5-year (P = .08) and 10-year (P = .13) RSRs. Conclusion: We report a lack of significant benefit in long-term outcomes for younger Hispanic patients with MM over time. This could be owing to multifactorial causes that need to be addressed to mitigate outcome disparities.
KW - Age-related survival
KW - Disparity
KW - Inequity in healthcare
KW - Outcomes
KW - Time-related trend
UR - http://www.scopus.com/inward/record.url?scp=85069907159&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069907159&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2019.06.010
DO - 10.1016/j.clml.2019.06.010
M3 - Article
C2 - 31377212
AN - SCOPUS:85069907159
SN - 2152-2650
VL - 19
SP - 619
EP - 623
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 10
ER -